MARKET

ADXS

ADXS

Advaxis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5324
+0.0024
+0.45%
Closed 17:52 04/01 EDT
OPEN
0.5300
PREV CLOSE
0.5300
HIGH
0.5500
LOW
0.5200
VOLUME
986.71K
TURNOVER
--
52 WEEK HIGH
10.80
52 WEEK LOW
0.2051
MARKET CAP
32.07M
P/E (TTM)
-0.1779
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADXS stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

EPS

ADXS News

More
  • Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets
  • Seeking Alpha - Article · 03/16 09:41
  • Advaxis EPS beats by $0.04
  • seekingalpha · 03/13 18:34
  • Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update
  • GlobeNewswire · 03/13 14:00
  • Advaxis Q1 EPS $(0.15) Down From $2.76 YoY, Sales $3M Down From $19.689M YoY
  • Benzinga · 03/13 13:03

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About ADXS

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
More

Webull offers kinds of Advaxis, Inc. stock information, including NASDAQ:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.